HLA haploidentical peripheral blood stem cell transplantation using reduced dose of posttransplantation cyclophosphamide for poor-prognosis or refractory leukemia and myelodysplastic syndrome
详细信息 查看全文
- 作者：Hirohisa Nakamae ; hirohisa@msic.med.osaka-cu.ac.jp" class="auth_mail" title="E-mail the corresponding author ; Hideo Koh ; Takako Katayama ; Mitsutaka Nishimoto ; Yoshiki Hayashi ; Yasuhiro Nakashima ; Takahiko Nakane ; Mika Nakamae ; Asao Hirose ; Masayuki Hino
- 刊名：Experimental Hematology
- 出版年：2015
- 出版时间：November 2015
- 年：2015
- 卷：43
- 期：11
- 页码：921-929.e1
- 全文大小：611 K
文摘
- •
We conducted a prospective pilot study of permissible dose reduction with PT/Cy.
- •
Incidence of grade II–IV acute GVHD tended to depend on PT/Cy dose.
- •
Cumulative incidence of chronic GVHD was low irrespective of PT/Cy dose.
- •
Infused CD34+ cell counts significantly correlated with grade of acute GVHD.
- •
PT/Cy 25 mg/kg × 2 yielded better outcomes compared with PT/Cy 25 mg/kg.